Australia Infant Phototherapy Device Market Forecast 2025–2033
According to Renub ResearchAustralia Infant Phototherapy Device Market is expected to reach US$ 2.47 billion by 2033, rising from US$ 1.88 billion in 2024, at a CAGR of 3.1% between 2025 and 2033. This steady growth is driven by rising cases of neonatal jaundice, increased awareness of early infant healthcare, and continuous advancements in non-invasive phototherapy technologies implemented across hospitals, maternity units, and neonatal intensive care units (NICUs).
Australia’s highly developed healthcare infrastructure, combined with nationwide emphasis on neonatal health outcomes, is creating strong demand for advanced phototherapy systems, particularly LED-based and mobile devices that offer superior safety, precision, and energy efficiency.
Australia Infant Phototherapy Device Market Outlook
Infant phototherapy devices are essential medical systems designed to treat neonatal jaundice, a common condition resulting from excess bilirubin buildup. These devices emit controlled wavelengths of blue light (typically 460–490 nm) that safely break down bilirubin, enabling the infant’s body to excrete it naturally. Phototherapy is highly effective, non-invasive, and often the first-line treatment recommended by pediatric specialists.
In Australia, phototherapy systems are widely adopted in maternity wards, postnatal care units, and NICUs, supported by advanced monitoring technologies and early health screening programs. The country’s healthcare ecosystem places strong emphasis on preventing complications such as kernicterus, making phototherapy an integral component of neonatal treatment protocols.
Most Australian hospitals have shifted toward LED-based phototherapy units, which offer:
- Higher energy efficiency
- Minimal heat production
- Reduced risk of infant dehydration
- Longer device lifespan
- Better irradiance control
With consistent government support, increasing birth rates in certain regions, and ongoing technological upgrades, the market for infant phototherapy devices continues to expand steadily across the country.
Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=australia-infant-phototherapy-device-market-p.php
Growth Drivers in the Australia Infant Phototherapy Device Market
Increasing Prevalence of Neonatal Jaundice
Neonatal jaundice is one of the most common medical conditions among newborns in Australia. Premature births, low birth weight, and liver immaturity are major contributors. Hospitals prioritize early diagnosis and rapid treatment to prevent severe complications.
According to recent data reviewed by KPMG, Australia recorded 289,100 births in 2023, increasing the overall need for neonatal screening and phototherapy equipment.
Greater public health awareness, routine bilirubin testing, and increased hospital readiness contribute to rising adoption of phototherapy devices across both public and private medical institutions. As screening becomes more widespread, more infants are diagnosed early, further boosting equipment demand.
Advances in Phototherapy Device Technology
Technological innovation remains one of the strongest growth drivers in the market. The transition from fluorescent lamps to sophisticated LED-based systems improves safety and enhances treatment outcomes. Advanced systems now offer:
- Adjustable light intensity for personalized treatment
- Energy-efficient LED arrays
- Wearable and fiber-optic phototherapy blankets
- Portable and hybrid units suitable for rural healthcare
One notable development occurred in March 2022, when Cook Medical launched the MINC+ Benchtop Incubator for IVF clinics across Australia. Although targeted at embryology, such product innovations indicate the country’s continual investment in neonatal and prenatal technologies, indirectly supporting demand for related phototherapy solutions.
As Australian hospitals continue upgrading their neonatal care infrastructure, the shift toward high-efficiency, low-heat devices is expected to accelerate significantly through 2033.
Government Support and Healthcare Infrastructure
Australia’s highly organized public healthcare system prioritizes maternal and neonatal care. Federal and state governments support hospital procurement programs, neonatal training, and expansion of rural outreach services. These initiatives ensure better access to phototherapy devices even in semi-urban and remote regions.
Government-backed funding for NICUs, rural clinics, and Indigenous health services has improved neonatal treatment availability and continues to push demand for both fixed and mobile phototherapy units. Australia’s consistent investment in improving infant survival outcomes directly strengthens the phototherapy market’s long-term outlook.
Challenges in the Australia Infant Phototherapy Device Market
Expensive Equipment and Budget Limitations
Advanced LED-based phototherapy systems, although more effective, are significantly more expensive than traditional fluorescent units. Smaller clinics, rural hospitals, and underfunded health centers may struggle to procure or replace high-cost equipment.
Decentralized procurement policies across states further contribute to uneven equipment distribution. This results in delayed device upgrades and limited treatment availability in lower-income or geographically isolated communities.
Limited Availability in Remote and Indigenous Regions
Healthcare access remains a notable challenge in Australia’s remote towns and Indigenous communities. Many of these areas lack advanced neonatal infrastructure or specialized phototherapy units. Newborns requiring treatment often need to be transported to larger hospitals—causing delays that may increase health risks.
To overcome this gap, investments in mobile phototherapy systems and trained neonatal outreach personnel are necessary. Expanding rural healthcare capacity remains an essential step in achieving equitable neonatal outcomes nationwide.
Australia Infant Phototherapy Fluorescent Lamps Device Market
Fluorescent lamps once dominated Australian neonatal wards due to their low initial cost. However, they generate more heat, consume more energy, and require frequent tube replacements. These disadvantages increase maintenance burdens, making them less desirable in modern facilities.
Although slowly being phased out in metropolitan hospitals, fluorescent devices remain common in budget-constrained or rural clinics. The shift to LED-based alternatives will continue suppressing the growth of this segment through the forecast period.
Australia Infant Phototherapy Mobile Device Market
Mobile phototherapy units are becoming increasingly important as Australia expands decentralized neonatal care. These devices are portable, easy to maneuver between departments, and perfect for clinics with limited space or resource constraints.
Mobile units support home-care environments for mild jaundice cases under clinical supervision. Their portability makes them indispensable for rural and remote outreach programs aiming to reduce neonatal health disparities.
Australia Infant Phototherapy Fixed Device Market
Fixed phototherapy units remain a staple in large public and private hospitals. These high-intensity systems deliver consistent light output and are ideal for busy maternity wards and NICUs where multiple patients require continuous observation.
Although less flexible than mobile units, fixed systems are valued for their durability, precision, and ability to support high patient volumes. Hospitals with well-equipped neonatal departments continue to prefer these units as primary phototherapy solutions.
Australia Infant Phototherapy Device Hospital Market
Hospitals account for the largest share of phototherapy device usage due to their advanced neonatal infrastructure and access to trained healthcare professionals. Public and private hospitals continually upgrade their systems to meet modern neonatal care standards.
Government subsidies, procurement grants, and early intervention policies strengthen this segment. High-intensity LED-based devices are increasingly deployed in NICUs, ensuring improved outcomes and better treatment efficiency.
Victoria Infant Phototherapy Device Market
Victoria is one of Australia’s most developed healthcare regions, with Melbourne serving as a central hub for advanced neonatal treatment. Public health initiatives and strong maternal-child health programs ensure consistent demand for modern phototherapy devices across hospitals and regional centers.
Queensland Infant Phototherapy Device Market
Queensland’s diverse geography, spanning large metropolitan areas and remote communities, creates strong demand for both fixed and mobile phototherapy units. Brisbane hosts several advanced pediatric hospitals, while rural clinics rely heavily on portable devices for newborn treatments. Government-funded outreach and maternal care programs continue driving market expansion.
Tasmania Infant Phototherapy Device Market
Tasmania maintains a strong healthcare system, with major hospitals in Hobart and Launceston equipped with modern phototherapy technology. Mobile equipment remains essential for smaller regional clinics. The state’s focus on rural neonatal outreach supports stable market growth for phototherapy products.
Western Australia Infant Phototherapy Device Market
Western Australia faces logistical challenges due to its vast territory and remote communities. Perth’s hospitals lead in neonatal care, but extending services to distant Aboriginal areas requires mobile and compact phototherapy devices. The state’s continued investment in maternal healthcare strengthens overall market demand.
Market Segmentation
Light Source
- Fluorescent Lamps
- Light Emitting Diodes (LEDs)
- Quartz Halogen Lamps
- Gas Discharge Tubes
Configuration
- Mobile Devices
- Fixed Devices
End User
- Hospitals
- Neonatal Clinics
Top States
- New South Wales
- Victoria
- Queensland
- Western Australia
- South Australia
- Australian Capital Territory
- Tasmania
- Northern Territory
Key Companies Covered
Ningbo David Medical Device Co., Ltd, Koninklijke Philips N.V., General Electric Company, Inspiration Healthcare Group Plc, Drägerwerk AG & Co. KGaA, Ibis Medical Equipment and Systems Pvt Ltd, Weyer GmbH, and Natus Medical Incorporated.
